TP53 (Ab-378) Antibody

What is TP53 (Ab-378) antibody and how does it recognize the target protein?

TP53 (Ab-378) is a polyclonal antibody raised in rabbits against a synthetic non-phosphopeptide derived from human p53 protein, specifically targeting the region surrounding the phosphorylation site of serine 378 (S-T-S(p)-R-H). This antibody recognizes both human and mouse p53 proteins . The antibody binds to the p53 protein through specific epitope recognition, which makes it valuable for detecting both wild-type and certain mutant forms of p53.

What are the primary research applications for TP53 (Ab-378) antibody?

TP53 (Ab-378) antibody has been validated for several key research applications including:

• Enzyme-Linked Immunosorbent Assay (ELISA) for quantitative detection of p53 protein levels

• Western Blotting (WB) at recommended dilutions of 1:500-1:3000 for protein expression analysis

• Immunoprecipitation studies to isolate p53 protein complexes

• Immunohistochemistry applications for detecting p53 in tissue samples

These applications are instrumental in studying p53's role as a tumor suppressor that regulates cell cycle and apoptosis pathways.

How does TP53 (Ab-378) antibody differ from other TP53 antibodies?

Unlike monoclonal antibodies like PAb419, PAb421, PAb607, and PAb248 that target specific epitopes , TP53 (Ab-378) is a polyclonal antibody that recognizes multiple epitopes centered around the serine 378 region. This characteristic provides broader recognition capabilities while potentially sacrificing some specificity compared to monoclonal alternatives. Additionally, while some antibodies are designed to specifically target mutant forms (such as those recognizing the R175H mutation ), TP53 (Ab-378) recognizes both wild-type and various mutant p53 proteins containing the targeted epitope region.

How can TP53 (Ab-378) antibody be utilized in studies of p53 phosphorylation status?

The TP53 (Ab-378) antibody targets the region around serine 378, making it particularly valuable for studying the phosphorylation dynamics at this position. Researchers can employ this antibody in comparative studies with phospho-specific antibodies to determine:

• The ratio of phosphorylated to non-phosphorylated p53 at serine 378

• How this phosphorylation changes during cell cycle progression or in response to DNA damage

• The impact of various kinase inhibitors on S378 phosphorylation status

When combined with techniques like lambda phosphatase treatment of samples, researchers can confirm the antibody's specificity and phosphorylation dependency.

What methodological approaches can address potential cross-reactivity issues with TP53 (Ab-378) antibody?

Cross-reactivity is an important consideration when working with polyclonal antibodies like TP53 (Ab-378). To minimize false positive results:

• Always include appropriate negative controls lacking p53 expression

• Perform validation with siRNA knockdown of TP53

• Consider using multiple antibodies targeting different p53 epitopes for confirmation

• Employ TP53-null cell lines as negative controls in immunoassays

• For critical findings, validate with orthogonal techniques beyond antibody-based detection

These validation steps are essential for ensuring result specificity, particularly when studying subtle changes in p53 expression or modification.

How can TP53 (Ab-378) antibody be implemented in studies of p53 mutational status in cancer specimens?

While TP53 (Ab-378) is not mutation-specific, researchers can strategically employ it alongside mutation-specific antibodies to develop comprehensive p53 mutation profiles. A methodological approach includes:

This multi-layered approach provides both protein-level confirmation and genetic information about p53 status in cancer specimens.

What are the optimal conditions for using TP53 (Ab-378) antibody in Western blotting applications?

For optimal Western blotting performance with TP53 (Ab-378) antibody:

Following these parameters will help ensure specific detection while minimizing background signal.

How can TP53 (Ab-378) antibody be integrated into multiplex immunoassay platforms?

For researchers developing multiplex assays to simultaneously detect multiple proteins:

• Conjugate TP53 (Ab-378) antibody to spectrally distinct fluorophores or magnetic microspheres

• Validate absence of cross-reactivity with other antibodies in the multiplex panel

• Establish standard curves using recombinant p53 protein at concentrations from 0.031-0.5 U/mL

• Determine the linear range (reported as 5.83-250 U/mL for some p53 immunoassays)

• Implement positive and negative controls according to manufacturer protocols

• Calculate intra-assay (target <5%) and inter-assay (target <7%) coefficients of variation

This approach enables simultaneous detection of p53 along with other proteins of interest, increasing throughput while reducing sample requirements.

What methodological considerations are important when using TP53 (Ab-378) for detecting p53 in clinical specimens?

When implementing TP53 (Ab-378) antibody for clinical research applications:

• Establish a cut-off threshold for positivity based on appropriate control populations

  • For reference, some TP53 autoantibody assays use 78 U/mL as a threshold providing 97.4% specificity

• Validate assay performance across multiple independent cohorts

• Calculate sensitivity and specificity values for your specific application

• Implement bootstrap techniques to construct 95% confidence intervals for threshold values

• Consider pre-analytical variables:

  • Specimen type (serum vs. plasma)

  • Storage conditions (temperature, freeze-thaw cycles)

  • Collection protocols (anticoagulants, processing time)

These considerations ensure reproducible and clinically meaningful results when applied to patient specimens.

How should researchers address weak or inconsistent signals when using TP53 (Ab-378) antibody?

When encountering weak or variable signals:

• Verify p53 expression levels in your cell system (some cell lines have low baseline expression)

• Consider inducing p53 expression with DNA damaging agents (e.g., doxorubicin, UV irradiation)

• Optimize protein extraction protocols:

  • Use freshly prepared lysis buffers with protease inhibitors

  • Avoid excessive heat during sample preparation

  • Consider using specialized nuclear extraction protocols for improved yield

• Adjust antibody concentration and incubation conditions

• Implement signal amplification strategies for low-abundance targets

• Verify antibody storage conditions and expiration dates

Remember that p53 expression can vary dramatically based on cell type, stress conditions, and experimental manipulations.

What are the critical considerations when interpreting immunoassay results using TP53 (Ab-378) antibody?

When analyzing data from TP53 (Ab-378) antibody experiments:

• Establish appropriate positive and negative controls for each experiment

• Consider the impact of post-translational modifications on antibody recognition

• Be aware that certain TP53 mutations may affect epitope recognition

• Interpret results in the context of p53's known biological functions:

  • Cell cycle regulation through p21 induction

  • Apoptosis regulation via BAX and FAS antigen expression

  • Interaction with Bcl-2 expression

• Validate critical findings with orthogonal techniques

How can researchers differentiate between specific and non-specific binding when using TP53 (Ab-378) antibody?

To distinguish true p53 signal from background:

• Implement peptide competition assays using the immunizing peptide

• Use TP53 knockout or knockdown samples as negative controls

• Compare patterns with multiple p53 antibodies targeting different epitopes

• Verify molecular weight (53 kDa for full-length p53) in Western blot applications

• Consider the cell-type specific expression patterns and subcellular localization

• Implement the solid-phase radioimmunoassay technique for quantitative analysis

These validation approaches help confirm that observed signals represent authentic p53 detection.

How can TP53 (Ab-378) antibody be utilized in studies of p53-protein interactions?

To investigate p53 protein complexes and binding partners:

• Implement co-immunoprecipitation protocols:

  • Use TP53 (Ab-378) as the capture antibody

  • Probe for interacting proteins in the immunoprecipitate

  • Consider crosslinking approaches for transient interactions

• Develop in vitro association assays similar to those used for p53-SV40 T-antigen studies

• Employ proximity ligation assays to visualize interactions in situ

• Use complementary approaches like mass spectrometry to identify novel binding partners

• Investigate how post-translational modifications around S378 affect protein interactions

These approaches help elucidate the complex network of p53 interactions that mediate its tumor suppressor functions.

What are the considerations for using TP53 (Ab-378) antibody in studies of p53 autoantibodies in cancer patients?

When researching the autoimmune response to p53:

• Distinguish between research antibody (TP53 Ab-378) and patient-derived autoantibodies

• Design capture assays using purified p53 protein as the target

• Consider testing for autoantibodies against both wild-type and mutant p53 forms

• Evaluate correlation with disease progression and treatment response

• Compare autoantibody detection with other biomarkers like CA125

• Establish appropriate cut-off values through rigorous statistical analysis

Research has shown that p53 autoantibodies can precede other cancer biomarkers, making this an important area for early detection research .

How can TP53 (Ab-378) antibody contribute to therapeutic development targeting mutant p53?

In therapeutic development contexts:

• Use as a screening tool to identify compounds that modify p53 expression or conformation

• Implement in cell-based assays evaluating p53 restoration approaches

• Compare with mutation-specific antibodies like those targeting R175H for therapeutic specificity

• Apply in immunohistochemistry panels for patient stratification in clinical trials

• Develop companion diagnostic approaches for p53-targeted therapies

The development of antibodies specifically targeting mutant p53 demonstrates the potential for immunotherapeutic approaches in targeting this common cancer driver .